Immucell reports preliminary Q1 revenue $8.1M vs. $7.3M last year

During the first quarter, the company recorded its all-time quarterly sales record, exceeding the previous all-time high mark set during the fourth quarter of 2024 by 4%. The strong sales during the first quarter of 2025 helped, in part, reduce the backlog of orders to $4M as of March 31 from $4.4M as of December 31, 2024. Sales recorded during both the six-month and twelve-month periods ended March 31 also set all-time records for those periods. “Any amount of backlog is too much because it means we are not fully meeting customer demand, but the level of production output and sales achieved during the last six months does demonstrate a strong improvement in our performance compared to 2023 and the first nine months of 2024,” commented Michael Brigham, president and CEO of ImmuCell (ICCC).